Growth hormone secretagogues
    3.
    发明授权
    Growth hormone secretagogues 失效
    生长激素促分泌素

    公开(公告)号:US06559150B2

    公开(公告)日:2003-05-06

    申请号:US09989040

    申请日:2001-11-21

    申请人: Philip A. Carpino

    发明人: Philip A. Carpino

    IPC分类号: C07D24186

    CPC分类号: C07D471/04 C07D487/04

    摘要: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; a &bgr;3 adrenergic receptor agonist; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920.

    摘要翻译: 本发明涉及式的化合物及其药学上可接受的盐,其中取代基如本说明书中所定义,其是生长激素分泌元素,并且其增加内源性生长激素的水平。 本发明化合物可用于治疗和预防骨质疏松症,充血性心力衰竭,与衰老有关的脆弱性,肥胖症; 加速骨折修复,减轻主要手术后的蛋白质分解代谢反应,减少慢性疾病引起的恶病质和蛋白质损失,加速伤口愈合,或加速烧伤患者或经历大手术的患者的恢复; 改善肌肉力量,流动性,皮肤厚度的维持,代谢稳态或肾动态平衡。 当与以下物质组合使用时,本发明的化合物也可用于治疗骨质疏松症:双膦酸盐化合物如阿仑膦酸盐; 雌激素,雌激素和可选的孕酮; β3肾上腺素能受体激动剂; 雌激素激动剂或拮抗剂; 或降钙素,以及对此有用的药物组合物。 此外,本发明涉及可用于增加人或其他动物中生长激素的内源性产生或释放的药物组合物,其包含有效量的本发明化合物和选自GHRP-6的生长激素促分泌素, Hexarelin,GHRP-1,生长激素释放因子(GRF),IGF-1,IGF-2或B-HT920。

    Cannabinoid receptor ligands and uses thereof
    5.
    发明授权
    Cannabinoid receptor ligands and uses thereof 失效
    大麻素受体配体及其用途

    公开(公告)号:US07232823B2

    公开(公告)日:2007-06-19

    申请号:US10853993

    申请日:2004-05-25

    IPC分类号: A61K31/4985 C07D487/04

    CPC分类号: C07D487/04

    摘要: Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein

    摘要翻译: 本文描述了作为大麻素受体配体的式(I)或(II)化合物及其在治疗与动物中的大麻素受体的介导相关的疾病中的用途

    Growth-hormone secretagogues
    7.
    发明授权
    Growth-hormone secretagogues 有权
    生长激素促分泌素

    公开(公告)号:US06482825B2

    公开(公告)日:2002-11-19

    申请号:US09734274

    申请日:2000-12-11

    IPC分类号: C07D47104

    摘要: This invention provides compounds of formula I and pharmaceutically-acceptable salts thereof, where the substituents are defined in the specification, which are growth hormone secretogogues useful for treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength , mobility, maintenance of skin thickness, metabolic homeostatis or renal homeostasis. Compounds of formula I in combination with: a bisphosphonate such as alendronate; estrogen, estrogens, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions thereof are useful in treating osteoporosis. This invention also provides pharmaceutical compositions comprising a compound of formula I and GHRP-6, Hexarelin, GHRP-1, GRF, IGF-1, IFG-2 or B-HT920.

    摘要翻译: 本发明提供式I化合物及其药学上可接受的盐,其中取代基在说明书中定义,其是可用于治疗和预防骨质疏松症,充血性心力衰竭,与衰老相关的脆弱性,肥胖症的生长激素分泌元件; 加速骨折修复,减轻主要手术后的蛋白质分解代谢反应,减少慢性疾病引起的恶病质和蛋白质损失,加速伤口愈合,或加速烧伤患者或经历大手术的患者的恢复; 改善肌肉力量,移动性,维持皮肤厚度,代谢平衡或肾脏体内平衡。 式I化合物与二膦酸盐如阿仑膦酸盐的组合: 雌激素,雌激素和任选的孕酮; 雌激素激动剂或拮抗剂; 或降钙素及其药物组合物可用于治疗骨质疏松症。 本发明还提供包含式I化合物和GHRP-6,Hexarelin,GHRP-1,GRF,IGF-1,IFG-2或B-HT920的药物组合物。

    Neuropeptide Y receptor antagonists
    8.
    发明授权
    Neuropeptide Y receptor antagonists 失效
    神经肽Y受体拮抗剂

    公开(公告)号:US06337332B1

    公开(公告)日:2002-01-08

    申请号:US09382418

    申请日:1999-08-24

    申请人: Philip A. Carpino

    发明人: Philip A. Carpino

    IPC分类号: A01N4354

    摘要: Compounds of the structures are useful for treating conditions related to an excess of neuropeptide Y including obesity and circulatory disorders.

    摘要翻译: 该结构的化合物可用于治疗与过量神经肽Y相关的病症,包括肥胖症和循环系统疾病。

    Growth-hormone secretagogues
    9.
    发明授权
    Growth-hormone secretagogues 有权
    生长激素促分泌素

    公开(公告)号:US06306875B1

    公开(公告)日:2001-10-23

    申请号:US09593582

    申请日:2000-06-13

    IPC分类号: A01N4342

    摘要: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula I.

    摘要翻译: 本发明涉及式的化合物及其药学上可接受的盐,其中取代基如本说明书中所定义,其是生长激素分泌元素,并且其增加内源性生长激素的水平。 本发明化合物可用于治疗和预防骨质疏松症,充血性心力衰竭,与衰老有关的脆弱性,肥胖症; 加速骨折修复,减轻主要手术后的蛋白质分解代谢反应,减少慢性疾病引起的恶病质和蛋白质损失,加速伤口愈合,或加速烧伤患者或经历大手术的患者的恢复; 改善肌肉力量,流动性,皮肤厚度的维持,代谢稳态或肾动态平衡。 当与以下物质组合使用时,本发明的化合物也可用于治疗骨质疏松症:双膦酸盐化合物如阿仑膦酸盐; 雌激素,雌激素和可选的孕酮; 雌激素激动剂或拮抗剂; 或降钙素,以及对此有用的药物组合物。 此外,本发明涉及可用于增加人或其他动物中生长激素的内源性产生或释放的药物组合物,其包含有效量的本发明化合物和选自GHRP-6的生长激素促分泌素, Hexarelin,GHRP-1,生长激素释放因子(GRF),IGF-1,IGF-2或B-HT920。 本发明还涉及可用于制备式I化合物的中间体。

    Heterocyclic compounds
    10.
    发明授权
    Heterocyclic compounds 有权
    杂环化合物

    公开(公告)号:US6107306A

    公开(公告)日:2000-08-22

    申请号:US259691

    申请日:1999-03-01

    摘要: This invention is directed to compounds of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula I.

    摘要翻译: 本发明涉及下式的化合物及其药学上可接受的盐,其中取代基如本说明书中所定义,其为生长激素分泌因子并且增加内源性生长激素的水平。 本发明化合物可用于治疗和预防骨质疏松症,充血性心力衰竭,与衰老有关的脆弱性,肥胖症; 加速骨折修复,减轻主要手术后的蛋白质分解代谢反应,减少慢性疾病引起的恶病质和蛋白质损失,加速伤口愈合,或加速烧伤患者或经历大手术的患者的恢复; 改善肌肉力量,流动性,皮肤厚度的维持,代谢稳态或肾动态平衡。 当与以下物质组合使用时,本发明的化合物也可用于治疗骨质疏松症:双膦酸盐化合物如阿仑膦酸盐; 雌激素,雌激素和可选的孕酮; 雌激素激动剂或拮抗剂; 或降钙素,以及用于其的药物组合物。 此外,本发明涉及可用于增加人或其他动物中生长激素的内源性产生或释放的药物组合物,其包含有效量的本发明化合物和选自GHRP-6的生长激素促分泌素, Hexarelin,GHRP-1,生长激素释放因子(GRF),IGF-1,IGF-2或B-HT920。 本发明还涉及可用于制备式I化合物的中间体。